Yapharm SRL
Yapharm reported total assets of 436,227 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026).
The score of Yapharm shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +25 % Total assets +133 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Yapharm's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 41,299 € | ||||
| Equity | 158,159 € | ||||
| Cash | 8,405 € | ||||
| EBITDA | 53,474 € | ||||
| Total assets | 436,227 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 24 Jul 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 09 Oct 2023
- Year ended 31 Dec 2021filed on 30 Sep 2022
Yapharm's financial analysis
- Solvency36.3%sector median: 37.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Yapharm
Yapharm's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0752.712.377
- VAT number
- BE0752712377
- Peppol
- Registered · 0208:0752712377 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 18 Aug 2020
- Registered office
- 1180 Uccle
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Yapharm (SRL) has been based in Uccle since 2020, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 41,299 € and equity of 158,159 €; its revenue is not published. Its solvency stands at 36.3%, below the median of its sector (37.6%).
Companies similar to Yapharm
Companies in the same business, of comparable size and area, outside its group.
- Farmadec Retail sale of pharmaceutical products Asse · balance sheet 554,731 €
- Pharmacie DE Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- Apotheek Oomen Retail sale of pharmaceutical products Antwerp · balance sheet 438,421 €
- Vereenooghe SEW Retail sale of pharmaceutical products Ledegem · balance sheet 426,561 €
- Dewez Invest Retail sale of pharmaceutical products Visé · balance sheet 419,029 €
- Natexis Retail sale of pharmaceutical products Auderghem · balance sheet 404,337 €
- Goethals Retail sale of pharmaceutical products Kortrijk · balance sheet 475,802 €
- Ankofar Retail sale of pharmaceutical products Aarschot · balance sheet 485,017 €
Frequently asked questions about Yapharm
What is the revenue of Yapharm?
Yapharm files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Yapharm?
In Belgium, the VAT number is the company number prefixed with BE: BE0752712377 for Yapharm, if the company is VAT-registered. Its company number (CBE) is 0752.712.377.
Where is the registered office of Yapharm?
According to the CBE register, the registered office of Yapharm is in 1180 Uccle.
What is the equity of Yapharm?
At the close of the 2025 financial year, the equity of Yapharm amounts to 158,159 €, a solvency of 36.3% of total assets.
Who manages Yapharm?
The register lists 1 active mandates at Yapharm. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Yapharm
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →